News
RHHBY
54.09
+1.50%
0.80
Roche’s Genentech announces new one-year data from Phase III Meerkat, Sandcat
TipRanks · 16h ago
Roche's experimental eye drug shows vision improvements in trials
Seeking Alpha · 18h ago
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
Barchart · 1d ago
Catalyst watch: Big bank earnings, CPI, and the Paris Auto Show
Seeking Alpha · 2d ago
Genentech announces FDA approval of Tecentriq combination
TipRanks · 3d ago
Roche Wins FDA Nod For Tecentriq Combination In Adjuvant Stage III DMMR Colon Cancer As 36-Month Disease-Free Survival Reaches 86% Versus 76% With Chemotherapy Alone In ATOMIC Trial
Benzinga · 3d ago
Zealand, Roche release phase 2 topline data for amylin analogue petrelintide
Seeking Alpha · 3d ago
Genentech's Tecentriq gains new indication for colon cancer
Seeking Alpha · 3d ago
Roche taps Chinese startup for drug discovery
Seeking Alpha · 3d ago
FDA approves Genentech’s atezolizumab combo for Stage III dMMR colon cancer
TipRanks · 3d ago
Pfizer’s Tukysa regimen approved in U.S. for front-line breast cancer
Seeking Alpha · 4d ago
Merck's Keytruda Is Dealt a Legal Setback. It's Good News for This Biotech Stock.
Barron‘s · 4d ago
QuidelOrtho: Margins Recover, Cash Does Not
Seeking Alpha · 4d ago
Natera: Priced To Perfection Amidst Rising Competitive Threats
Seeking Alpha · 4d ago
Pharma lobby group sues Trump administration over MFN pricing
Seeking Alpha · 4d ago
Roche Holding AG (RHHVF) Gets a Hold from Berenberg Bank
TipRanks · 5d ago
Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration
Benzinga · 5d ago
Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC
PR Newswire · 5d ago
Genmab: Epkinly Shines In Phase 3 DLBCL Trial
Seeking Alpha · 5d ago
Alector price target raised to $3 from $2 at Morgan Stanley
TipRanks · 6d ago
More
Webull provides a variety of real-time RHHBY stock news. You can receive the latest news about Roche Hldg through multiple platforms. This information may help you make smarter investment decisions.
About RHHBY
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.